Paper41103296
Metabolomic profiling reveals novel biomarkers and therapeutic targets in Legg-Calvé-Perthes disease: a comprehensive analysis of peripheral blood and endothelial function.
Zi S and 7 others. Front Physiol, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Metabolomic profiling reveals novel biomarkers and therapeutic targets in Legg-Calvé-Perthes disease: a comprehensive analysis of peripheral blood and endothelial function. Papers, record 41103296. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41103296
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Metabolomic profiling reveals novel biomarkers and therapeutic targets in Legg-Calvé-Perthes disease: a comprehensive analysis of peripheral blood and endothelial function.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33843788 | Hip Morphology in Early-stage LCPD: Is There an Argument for Anatomic-specific Containment? | J Pediatr Orthop | 2021 | https://conductscience.org/library/papers/33843788 | PubMed |
| 2 | 36274080 | Development of acetabular retroversion in LCPD hips-an observational radiographic study from early stage to healing. | Arch Orthop Trauma Surg | 2023 | https://conductscience.org/library/papers/36274080 | PubMed |
| 3 | 35628529 | Bone Health in Children with Rheumatic Disorders: Focus on Molecular Mechanisms, Diagnosis, and Management. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35628529 | PubMed |
| 4 | 33573577 | Sanguinarine: A Double-Edged Sword of Anticancer and Carcinogenesis and Its Future Application Prospect. | Anticancer Agents Med Chem | 2021 | https://conductscience.org/library/papers/33573577 | PubMed |
| 5 | 38315432 | Legg-Calvé-Perthes Disease: Diagnosis, Decision Making, and Outcome. | Curr Sports Med Rep | 2024 | https://conductscience.org/library/papers/38315432 | PubMed |
| 6 | 40108238 | Metabolomic profiles in serum uncover novel biomarkers in children with Williams-Beuren syndrome. | Sci Rep | 2025 | https://conductscience.org/library/papers/40108238 | PubMed |
| 7 | 33938444 | Surgical Treatments for Legg-Calvé-Perthes Disease: Comprehensive Review. | Interact J Med Res | 2021 | https://conductscience.org/library/papers/33938444 | PubMed |
| 8 | 37417786 | A microfluidic platform integrating dynamic cell culture and dielectrophoretic manipulation for in situ assessment of endothelial cell mechanics. | Lab Chip | 2023 | https://conductscience.org/library/papers/37417786 | PubMed |
| 9 | 29155310 | Legg-Calvé-Perthes disease. | Orthop Traumatol Surg Res | 2018 | https://conductscience.org/library/papers/29155310 | PubMed |
| 10 | 32526406 | The role of miR-150 regulates bone cell differentiation and function. | Bone | 2021 | https://conductscience.org/library/papers/32526406 | PubMed |
| 11 | 33220290 | Increased circulating CD31+/CD42b-EMPs in Perthes disease and inhibit HUVECs angiogenesis via endothelial dysfunction. | Life Sci | 2021 | https://conductscience.org/library/papers/33220290 | PubMed |
| 12 | 33809098 | Potential Effect of Pseudevernia furfuracea (L.) Zopf Extract and Metabolite Physodic Acid on Tumour Microenvironment Modulation in MCF-10A Cells. | Biomolecules | 2021 | https://conductscience.org/library/papers/33809098 | PubMed |
| 13 | 34740784 | MicroRNA sequence analysis of plasma exosomes in early Legg-Calvé-Perthes disease. | Cell Signal | 2022 | https://conductscience.org/library/papers/34740784 | PubMed |
| 14 | 37422572 | [Legg-Calvé-Perthes disease]. | Radiologie (Heidelb) | 2023 | https://conductscience.org/library/papers/37422572 | PubMed |
| 15 | 29727671 | Metabolomics and Isotope Tracing. | Cell | 2018 | https://conductscience.org/library/papers/29727671 | PubMed |
| 16 | 35292045 | Legg-Calvé-Perthes disease overview. | Orphanet J Rare Dis | 2022 | https://conductscience.org/library/papers/35292045 | PubMed |
| 17 | 36300786 | In vitrovascularization of hydrogel-based tissue constructs via a combined approach of cell sheet engineering and dynamic perfusion cell culture. | Biofabrication | 2022 | https://conductscience.org/library/papers/36300786 | PubMed |
| 18 | 37303951 | Construction of ceRNA network based on RNA-seq for identifying prognostic lncRNA biomarkers in Perthes disease. | Front Genet | 2023 | https://conductscience.org/library/papers/37303951 | PubMed |
| 19 | 28106508 | GelMA-Encapsulated hDPSCs and HUVECs for Dental Pulp Regeneration. | J Dent Res | 2017 | https://conductscience.org/library/papers/28106508 | PubMed |
| 20 | 36988742 | Combined targeted and untargeted high-resolution mass spectrometry analyses to investigate metabolic alterations in pompe disease. | Metabolomics | 2023 | https://conductscience.org/library/papers/36988742 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41103296
GET https://conductscience.org/api/papers/v1/41103296/references?page=2